Durvalumab vs Tofacitinib

## Durvalumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Tofacitinib**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Tofacitinib**: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Tofacitinib — 3.2 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Tofacitinib — C16H20N6O.

**Molecular Weight**: Durvalumab — N/A; Tofacitinib — 312.3700 g/mol.

**Type**: Durvalumab — Antibody; Tofacitinib — Small molecule.